Stock Price Forecast
The 5 analysts offering 12-month price forecasts for Dare Bioscience Inc have a median target of 6.00, with a high estimate of 17.00 and a low estimate of 3.00. The median estimate represents a +282.17% increase from the last price of 1.57.
Similarly What rating is dare Bioscience? The consensus rating score for Daré Bioscience is 3.00 while the average consensus rating score for medical companies is 2.73.
How much is target DARE? Stock Price Targets
| High | $17.00 |
|---|---|
| Median | $6.00 |
| Low | $3.00 |
| Average | $7.20 |
| Current Price | $1.4100 |
Additionally, When was DARE Stock FDA approved?
Development Timeline for Xaciato
| Date | Article |
|---|---|
| Dec 7, 2021 | Approval FDA Approves Xaciato (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis |
| Aug 9, 2021 | Daré Bioscience Announces FDA Acceptance and Priority Review of New Drug Application for DARE-BV1 for the Treatment of Bacterial Vaginosis |
• 8 déc. 2021
What is the stock of DARE Pharma?
(DARE) Stock Price, News, Quote & History – Yahoo Finance.
…
Performance Outlook.
| Previous Close | 1.4900 |
|---|---|
| 52 Week Range | 1.2000 – 2.5100 |
| Volume | 6,361,573 |
| Avg. Volume | 2,143,816 |
Is DARE Stock FDA approved? On December 7, 2021, Daré announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.
Is DARE Stock News approved by the FDA? Dare Bioscience (NASDAQ:DARE) recently rallied 30.0% on the news of FDA approval of XACIATO for bacterial vaginosis in women on Dec. 7, 2021. Since the FDA approval DARE stock price has declined for no fundamental reason other than the stock market weakness.
Can I dare Bioscience bacterial vaginosis? DARE-BV1 is an investigational thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% designed as a one-time vaginally-administered treatment for bacterial vaginosis.
Who is the CEO of DARE Bioscience?
Sabrina Martucci Johnson. Ms. Johnson founded Daré Bioscience Operations in 2015 and has served as President, CEO and a member of the Board of Directors since its inception and following its business combination with Cerulean Pharma in July 2017, when the Company was renamed Daré Bioscience.
What is a Pdufa from FDA? The Prescription Drug User Fee Act (PDUFA) was created by Congress in 1992 and authorizes FDA to collect fees from companies that produce certain human drug and biological products.
What is DARE Bioscience press release?
Press Releases
- Daré Bioscience to Host Full-year 2021 Financial Results and Company Update Conference Call and Webcast on March 31, 2022. 03-24-2022.
- Daré Bioscience to Present at the Maxim 2022 Virtual Growth Conference. 03-22-2022.
- Daré Bioscience to Participate in Upcoming Conferences. 03-02-2022.
What is Xaciato? XACIATO is a lincosamide antibacterial indicated for the. treatment of bacterial vaginosis in female patients 12 years of. age and older. (
How much does an IND cost?
FY 2014 – FY 2017
| Submission Type | FY 14 | FY 15 |
|---|---|---|
| Drug Applications | ||
| IND | $459.0 | $550.3 |
| NDA Clinical Data – NME | $5,646.4 | $5,250.5 |
| NDA with Clinical Data – Non-NME | $1,845.2 | $1,356.2 |
• 13 août 2018
What is the difference between BLA and NDA?
Whereas a new drug application (NDA) is used for drugs subject to the drug approval provisions of the FDC Act, a biologics license application (BLA) is required for biological products subject to licensure under the PHS Act. FDA form 356h is used for both NDA and BLA submissions.
How long does BLA approval take? Review Timeline
As per the Prescription Drug User Fee Act (PDUFA), the FDA agreed to review the majority of BLAs within 10 months of 60 day filing and for the priority submissions it has been cut down to 6 months of 60 day filing date.
What is the stock of Dare Pharma? (DARE) Stock Price, News, Quote & History – Yahoo Finance.
…
Performance Outlook.
| Previous Close | 1.4900 |
|---|---|
| 52 Week Range | 1.2000 – 2.5100 |
| Volume | 6,361,573 |
| Avg. Volume | 2,143,816 |
What is the next dare bioscience event?
Clinical and Scientific Events
- 09-08-2021 to 09-10-2021. 13th European Congress on Menopause and Andropause. …
- 07-25-2021 to 07-29-2021. 2021 Controlled Release Society Virtual Annual Meeting. …
- 03-09-2020. …
- 10-07-2019 to 10-08-2019. …
- 08-08-2019 to 08-10-2019. …
- 07-22-2019 to 07-24-2019.
What happens on Pdufa date? In United States pharmaceutical regulatory practice, the PDUFA date is the colloquial name for the date by which the Food and Drug Administration must respond to a New Drug Application or a Biologics License Application.
What is the new drug DARE?
DARE-BV1, a gel that treats bacterial vaginosis, was granted FDA approval on its Prescription Drug User Fee Act (PDUFA) date today. DARE-BV1 (clindamycin phosphate) was approved today by the US Food and Drug Administration (FDA) to treat bacterial vaginosis.
How much does it cost to apply for FDA approval? FDA Annual Establishment Registration Fee – $5,672 (2022)
The FDA charges a flat registration fee for for all businesses interested in manufacturing or marketing their products and devices in the United States. If your company is already registered with the FDA, then there is no additional charge.
Who pays for experimental drugs?
In accordance with 21 CFR 312.8(b)(1), a sponsor must obtain prior authorization from FDA to charge for its investigational drugs, including investigational uses of its approved drugs.
How much does it cost to get FDA approval for supplements? Dietary supplement comes under food regulations, the fees is same as food facility. LMG fees for dietary supplement facility registration and FDA agent service is $349/year.
